Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DH
stocks logo

DH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
59.56M
-4.38%
0.060
-25.21%
57.45M
-2.95%
0.059
+17.6%
58.85M
-3.12%
0.069
-1.71%
Estimates Revision
The market is revising Upward the revenue expectations for Definitive Healthcare Corp. (DH) for FY2025, with the revenue forecasts being adjusted by 0.41% over the past three months. During the same period, the stock price has changed by -36.00%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.41%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+4.01%
In Past 3 Month
Stock Price
Go Down
down Image
-36.00%
In Past 3 Month
Wall Street analysts forecast DH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DH is 3.52 USD with a low forecast of 3.00 USD and a high forecast of 4.06 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast DH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DH is 3.52 USD with a low forecast of 3.00 USD and a high forecast of 4.06 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
4 Hold
1 Sell
Hold
Current: 2.560
sliders
Low
3.00
Averages
3.52
High
4.06
Current: 2.560
sliders
Low
3.00
Averages
3.52
High
4.06
Canaccord
David Hynes
Hold
downgrade
$5 -> $4
2025-11-10
Reason
Canaccord
David Hynes
Price Target
$5 -> $4
2025-11-10
downgrade
Hold
Reason
Canaccord analyst David Hynes lowered the firm's price target on Definitive Healthcare to $4 from $5 and keeps a Hold rating on the shares. The firm said the positive takeaways here are that new customer acquisition exceeded internal expectations, the firm is making progress on mitigating downsell pressures, and gross revenue retention should be up year-over-year.
Baird
Neutral
downgrade
$4 -> $3
2025-11-07
Reason
Baird
Price Target
$4 -> $3
2025-11-07
downgrade
Neutral
Reason
Baird lowered the firm's price target on Definitive Healthcare to $3 from $4 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results.
Stifel
Buy
downgrade
$6 -> $5
2025-11-07
Reason
Stifel
Price Target
$6 -> $5
2025-11-07
downgrade
Buy
Reason
Stifel lowered the firm's price target on Definitive Healthcare to $5 from $6 and keeps a Buy rating on the shares. While "encouraged" by management's actions to reaccelerate growth and improve profitability, the firm acknowledges that the stock's valuation reflects the absence of near-term catalysts as the company's turnaround continues.
Baird
Joe Vruwink
Neutral
maintain
$3 -> $4
2025-08-08
Reason
Baird
Joe Vruwink
Price Target
$3 -> $4
2025-08-08
maintain
Neutral
Reason
Baird analyst Joe Vruwink raised the firm's price target on Definitive Healthcare to $4 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results and where its outlook was nudged higher.
Stifel
Buy
downgrade
$6 -> $5
2025-05-09
Reason
Stifel
Price Target
$6 -> $5
2025-05-09
downgrade
Buy
Reason
Goldman Sachs
Kash Rangan
Hold
Maintains
$4.5 → $3
2025-03-04
Reason
Goldman Sachs
Kash Rangan
Price Target
$4.5 → $3
2025-03-04
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Definitive Healthcare Corp (DH.O) is 10.00, compared to its 5-year average forward P/E of 50.38. For a more detailed relative valuation and DCF analysis to assess Definitive Healthcare Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
50.38
Current PE
10.00
Overvalued PE
99.88
Undervalued PE
0.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
23.07
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
39.84
Undervalued EV/EBITDA
6.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.24
Current PS
0.00
Overvalued PS
9.54
Undervalued PS
0.94
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

DH News & Events

Events Timeline

(ET)
2025-11-06
18:28:18
Definitive Healthcare increases FY25 adjusted EPS forecast to 23c-24c, up from 22c-23c
select
2025-11-06
18:25:30
Definitive Healthcare projects Q4 adjusted EPS between 5c and 6c, in line with consensus of 6c.
select
2025-11-06
18:24:28
Definitive Healthcare announces Q3 adjusted EPS of 7 cents, surpassing consensus estimate of 5 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11:00 AMNASDAQ.COM
Advent International Invests $2.35 Billion to Make NIQ Its Leading Investment

  • Advent International's Investment: Boston-based Advent International has acquired a new stake in NIQ Global Intelligence plc, purchasing 149,380,246 shares valued at approximately $2.35 billion, making it the fund's largest holding.

  • Financial Overview of NIQ: As of September 30, 2025, NIQ reported trailing twelve months revenue of $4.01 billion and a net loss of $434.36 million, with shares priced at $14.18, which is 30.46% below its 52-week high.

  • NIQ's Market Position: NIQ operates globally with over 38,000 employees, providing an AI-powered consumer intelligence platform that analyzes shopping data to deliver insights for brands and retailers, playing a crucial role in consumer behavior analysis.

  • Investment Implications: Advent's significant investment suggests confidence in NIQ's long-term value despite current market pressures, as the company seeks to convert its data capabilities into consistent free cash flow while managing its debt load.

[object Object]
Preview
7.5
12-04Globenewswire
De Havilland Partners with Avincis to Enhance CL Series Aircraft Services
  • Collaboration Agreement: De Havilland and Avincis have established a partnership where Avincis transfers its ADS-B and FMS supplemental type certificates for CL aircraft to De Havilland, enhancing the spare parts catalog and improving access to critical system solutions for global CL aircraft operators.
  • Market Responsiveness: This collaboration enables De Havilland to better serve Avincis, the largest operator of CL-415 aircraft globally, which is expected to enhance customer satisfaction and strengthen market competitiveness.
  • Design and Maintenance Capabilities: Avincis brings over 20 years of operational experience with CL-415 aircraft, providing robust design and maintenance capabilities that will deliver high-quality solutions to global CL aircraft operators, further solidifying its market position.
  • Commitment to Ongoing Investment: This partnership is part of De Havilland's ongoing investment and commitment to CL aircraft customers, demonstrating the company's dedication to enhancing its service capabilities in the global aviation market through collaboration with Avincis.
[object Object]
Preview
4.0
12-03NASDAQ.COM
Daily Upgrade Report for Validea Kenneth Fisher Strategy - December 3, 2025

  • Validea's Upgrade for Definitive Healthcare Corp: The stock rating for Definitive Healthcare Corp (DH) improved from 58% to 70% based on Kenneth Fisher's Price/Sales Investor model, indicating a positive shift in the company's fundamentals and valuation.

  • Company Overview: Definitive Healthcare Corp specializes in healthcare commercial intelligence, utilizing a SaaS platform that leverages AI and ML to provide analytics and insights for optimizing product development and market strategies.

  • Kenneth Fisher's Investment Philosophy: Kenneth Fisher, a prominent money manager and author, is known for popularizing the price/sales ratio as a method for identifying attractive stocks, drawing from his family's legacy in growth investing.

  • Validea's Research Service: Validea offers investment research based on the strategies of renowned investors, providing stock analysis and model portfolios aimed at long-term market outperformance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Definitive Healthcare Corp (DH) stock price today?

The current price of DH is 2.56 USD — it has decreased -1.16 % in the last trading day.

arrow icon

What is Definitive Healthcare Corp (DH)'s business?

Definitive Healthcare Corp. is engaged in transforming data, analytics, and expertise into healthcare commercial intelligence. The Company’s solutions are designed to provide information on healthcare providers and their activities to help its customers optimize everything from product development to go-to-market planning and sales and marketing execution. Its software-as-a-service (SaaS) platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers and improving win rates with detailed contextual information. It transforms data into intelligence through artificial intelligence (AI) and machine learning (ML) algorithms that ingest, cleanse, link, and analyze the data to create new intelligence and analytics. Its business is conducted through AIDH TopCo, LLC (Definitive OpCo).

arrow icon

What is the price predicton of DH Stock?

Wall Street analysts forecast DH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DH is 3.52 USD with a low forecast of 3.00 USD and a high forecast of 4.06 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Definitive Healthcare Corp (DH)'s revenue for the last quarter?

Definitive Healthcare Corp revenue for the last quarter amounts to 60.05M USD, decreased -4.23 % YoY.

arrow icon

What is Definitive Healthcare Corp (DH)'s earnings per share (EPS) for the last quarter?

Definitive Healthcare Corp. EPS for the last quarter amounts to -0.14 USD, decreased -87.50 % YoY.

arrow icon

What changes have occurred in the market's expectations for Definitive Healthcare Corp (DH)'s fundamentals?

The market is revising Upward the revenue expectations for Definitive Healthcare Corp. (DH) for FY2025, with the revenue forecasts being adjusted by 0.41% over the past three months. During the same period, the stock price has changed by -36.00%.
arrow icon

How many employees does Definitive Healthcare Corp (DH). have?

Definitive Healthcare Corp (DH) has 782 emplpoyees as of December 05 2025.

arrow icon

What is Definitive Healthcare Corp (DH) market cap?

Today DH has the market capitalization of 362.63M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free